title: Predictors of outcomes in the treatment of urge urinary incontinence in women.
abstract: OBJECTIVE
  Women with urge predominant urinary incontinence received active intervention (drug therapy alone or combined with behavioral therapy) for 10 weeks, then stopped all therapy and were followed for 6 months more. In this planned secondary analysis, we aimed to identify predictors of therapeutic success at 10 weeks (> or =70% reduction in incontinence) and of ability to discontinue treatment and sustain improvements 6 months later.
  
  
  METHODS
  Using data from 307 women, we performed logistic regression to identify predictors for outcomes described above.
  
  
  RESULTS
  After controlling for group, only younger age was associated with short-term success (OR 0.8, 95% CI 0.66, 0.96). At 6 months, controlling for group and short-term outcome, only greater anterior vaginal wall prolapse was associated with successful discontinuation (POP-Q point Aa; OR 1.33, 95% CI 1.03, 1.7).
  
  
  CONCLUSIONS
  These findings are not of sufficient strength to justify withholding conservative therapies but might be used to promote realistic expectations when counseling patients.
authors.affiliation: Division Women's Pelvic Medicine and Reconstructive Surgery, Department of Obstetrics and Gynecology, University of Alabama at Birmingham, Birmingham, AL 35233, USA. hrichter@uab.edu
authors.forename: Holly E
authors.initials: HE
authors.lastname: Richter
authors.forename: Kathryn L
authors.initials: KL
authors.lastname: Burgio
authors.forename: Toby C
authors.initials: TC
authors.lastname: Chai
authors.forename: Stephen R
authors.initials: SR
authors.lastname: Kraus
authors.forename: Yan
authors.initials: Y
authors.lastname: Xu
authors.forename: Lee
authors.initials: L
authors.lastname: Nyberg
authors.forename: Linda
authors.initials: L
authors.lastname: Brubaker
mesh_terms: D000328:Adult; D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D001521:Behavior Therapy; D001559:Benzhydryl Compounds / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D016001:Confidence Intervals; D003408:Cresols / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D016015:Logistic Models; D008875:Middle Aged; D018727:Muscarinic Antagonists / Q000627:therapeutic use*; D016017:Odds Ratio; D010665:Phenylpropanolamine / Q000627:therapeutic use*; D057566:Self Report; D000068737:Tolterodine Tartrate; D016896:Treatment Outcome; D053202:Urinary Incontinence, Urge / Q000628:therapy*; D055815:Young Adult
chemical_list: D001559:Benzhydryl Compounds; D003408:Cresols; D018727:Muscarinic Antagonists; D010665:Phenylpropanolamine; D000068737:Tolterodine Tartrate